WO1994005332A3 - Glycolation de macromolecules glycosylees - Google Patents

Glycolation de macromolecules glycosylees Download PDF

Info

Publication number
WO1994005332A3
WO1994005332A3 PCT/US1993/008196 US9308196W WO9405332A3 WO 1994005332 A3 WO1994005332 A3 WO 1994005332A3 US 9308196 W US9308196 W US 9308196W WO 9405332 A3 WO9405332 A3 WO 9405332A3
Authority
WO
WIPO (PCT)
Prior art keywords
macromolecule
macromolecules
polyalkylene glycol
glycosylated
diamino compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/008196
Other languages
English (en)
Other versions
WO1994005332A2 (fr
Inventor
Timkulu Thabiso M
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlex Laboratories Inc
Original Assignee
Berlex Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlex Laboratories Inc filed Critical Berlex Laboratories Inc
Priority to AU50981/93A priority Critical patent/AU5098193A/en
Publication of WO1994005332A2 publication Critical patent/WO1994005332A2/fr
Publication of WO1994005332A3 publication Critical patent/WO1994005332A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé de couplage de glycols à des macromolécules par glycosylations sur ces dernières et non par des groupes amino ou carboxyle sur le squelette de celles-ci. On produit ainsi des macromolécules à réponse immunogène réduite et à activité maintenue. Ledit procédé de glycosylation d'une macromolécule glycosylée consiste à activer un glycol de polyalkylène; à faire réagir le glycol de polyalkylène activé avec un composé diamino, le glycol de polyalkylène activé étant couplé au composé diamino par un de ses groupes amino; à oxyder la macromolécule afin d'activer au moins un groupe glycosyl qu'elle contient; et à faire réagir le glycol de polyalkylène couplé au composé diamino avec le groupe glycosyl oxydé dans la macromolécule. On obtient ainsi une macromolécule glycosylée glycolée dans laquelle le glycol est lié à la macromolécule par ses glycosylations.
PCT/US1993/008196 1992-09-01 1993-09-01 Glycolation de macromolecules glycosylees Ceased WO1994005332A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50981/93A AU5098193A (en) 1992-09-01 1993-09-01 Glycolation of glycosylated macromolecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93777992A 1992-09-01 1992-09-01
US07/937,779 1992-09-01

Publications (2)

Publication Number Publication Date
WO1994005332A2 WO1994005332A2 (fr) 1994-03-17
WO1994005332A3 true WO1994005332A3 (fr) 1994-04-14

Family

ID=25470393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/008196 Ceased WO1994005332A2 (fr) 1992-09-01 1993-09-01 Glycolation de macromolecules glycosylees

Country Status (2)

Country Link
AU (1) AU5098193A (fr)
WO (1) WO1994005332A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69734443T2 (de) * 1996-01-08 2006-07-13 Genentech, Inc., South San Francisco Ob-rezeptor und liganden
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
CA2277757C (fr) 1997-01-15 2008-09-16 Phoenix Pharmacologics, Inc. Facteur de necrose des tumeurs modifie
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
EE05111B1 (et) 1998-10-16 2008-12-15 Biogen, Incorporated Interferoon-beetaga sulandatud valgud ja nende kasutamine
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
EP2305312B1 (fr) * 2001-10-10 2015-03-04 ratiopharm GmbH Remodelage et glycoconjugation de l'hormone folliculo-stimulante (FSH)
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
RU2329274C2 (ru) * 2002-09-11 2008-07-20 Фрезениус Каби Дойчланд Гмбх Способ получения производных гидроксиалкилкрахмала
CA2506244C (fr) 2002-11-18 2012-10-30 Phoenix Pharmacologics, Inc. Methodes d'inhibition d'une replication virale in vivo
CN102212019B (zh) 2003-03-14 2015-05-27 蔚所番有限公司 支化水溶性聚合物及其缀合物
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2004091499A2 (fr) 2003-04-09 2004-10-28 Neose Technologies, Inc. Formation intracellulaire de conjugues de peptides
WO2006127896A2 (fr) 2005-05-25 2006-11-30 Neose Technologies, Inc. Facteur ix glycopegyle
EP1615945B1 (fr) 2003-04-09 2011-09-28 BioGeneriX AG Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
WO2005012484A2 (fr) 2003-07-25 2005-02-10 Neose Technologies, Inc. Conjugues anticorps-toxines
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
AU2004293103C1 (en) 2003-11-24 2010-12-02 Ratiopharm Gmbh Glycopegylated erythropoietin
JP2007515410A (ja) * 2003-12-03 2007-06-14 ネオス テクノロジーズ インコーポレイテッド ＧｌｙｃｏＰＥＧ化卵胞刺激ホルモン
US8361961B2 (en) 2004-01-08 2013-01-29 Biogenerix Ag O-linked glycosylation of peptides
EP1745141B2 (fr) 2004-05-04 2019-09-25 Novo Nordisk Health Care AG Glycoformes de facteur vii o-liees et leur procede de fabrication
WO2006010143A2 (fr) 2004-07-13 2006-01-26 Neose Technologies, Inc. Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon [glp-1]
EP1799249A2 (fr) 2004-09-10 2007-06-27 Neose Technologies, Inc. Interferon alpha glycopegyle
EP1814573B1 (fr) 2004-10-29 2016-03-09 ratiopharm GmbH Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf)
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (fr) 2005-11-03 2007-05-18 Neose Technologies, Inc. Purification de sucre de nucleotide en utilisant des membranes
EP2010222A1 (fr) 2006-03-31 2009-01-07 Baxter International Inc. Facteur viii pégylé
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
WO2008154639A2 (fr) 2007-06-12 2008-12-18 Neose Technologies, Inc. Procédé amélioré pour la production de sucres de nucléotide
MX2010002448A (es) 2007-08-27 2010-10-04 Biogenerix Ag Formulacion liquida del g-csf conjugado.
PL2245056T4 (pl) 2008-01-22 2016-01-29 Araim Pharmaceuticals Inc Peptydy i analogi peptydowe chroniące tkanki do zapobiegania i leczenia chorób i schorzeń związanych z uszkodzeniem tkanek
CN103497247A (zh) 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
EP2672260A1 (fr) 2008-05-13 2013-12-11 Advanced Liquid Logic, Inc. Procédés, systèmes et dispositifs associés à un positionneur de gouttelettes
SG178051A1 (en) 2009-07-27 2012-03-29 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG178141A1 (en) 2009-07-27 2012-03-29 Baxter Int Blood coagulation protein conjugates
CN104530182A (zh) 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
DK2654794T3 (da) 2010-12-22 2020-06-08 Baxalta GmbH Materialer og fremgangsmåder til konjugering af et vandopløseligt fedtsyrederivat til et protein
EP2838566A2 (fr) 2012-04-16 2015-02-25 Cantab Biopharmaceuticals Patents Limited Médicaments à administration souscutanée optimisés
WO2017189988A1 (fr) 2016-04-29 2017-11-02 Araim Pharmaceuticals, Inc. Peptides protecteurs tissulaires permettant de prévenir et traiter des maladies et des troubles associés à une lésion tissulaire

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006546A1 (fr) * 1988-01-20 1989-07-27 Cetus Corporation Conjugaison d'un polymere avec la proteine csf-1
EP0442724A2 (fr) * 1990-02-13 1991-08-21 Kirin-Amgen, Inc. IL-6 humaine modifiée
WO1993012220A1 (fr) * 1991-12-12 1993-06-24 Berlex Laboratories, Inc. ANTICORPS DE RECOMBINAISON ET CHIMERIQUES CONTRE c-erbB-2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006546A1 (fr) * 1988-01-20 1989-07-27 Cetus Corporation Conjugaison d'un polymere avec la proteine csf-1
EP0442724A2 (fr) * 1990-02-13 1991-08-21 Kirin-Amgen, Inc. IL-6 humaine modifiée
WO1993012220A1 (fr) * 1991-12-12 1993-06-24 Berlex Laboratories, Inc. ANTICORPS DE RECOMBINAISON ET CHIMERIQUES CONTRE c-erbB-2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 103, no. 11, 16 September 1985, Columbus, Ohio, US; abstract no. 84021 *
VERONESE F. ET AL.: "SURFACE MOFIFICATION OF PROTEINS. ACTIVATION OF MONOMETHOXY-POLYETHYLENE GLYCOLS BY PHENYLCHLOROFORMATES AND MODIFICATION OF RIBONUCLEASE AND SUPEROXIDE DISMUTASE.", APPL. BIOCHEM. BIOTECHNOL., vol. 11, no. 2, 1985, pages 141 - 152 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography

Also Published As

Publication number Publication date
WO1994005332A2 (fr) 1994-03-17
AU5098193A (en) 1994-03-29

Similar Documents

Publication Publication Date Title
WO1994005332A3 (fr) Glycolation de macromolecules glycosylees
AU3868489A (en) Portable personal banking system
EP2260872A3 (fr) Polymères conjugués de l' interferon beta-1A et leurs utilisations
CA2064835A1 (fr) Nouvelle composition complexe emulsifiee
AU671554B2 (en) Silanes with hydrophilic groups, their synthesis and use as surfactants in aqueous media
CA2069244A1 (fr) Liposome lie a une proteine et contenant un medicament
AU6475394A (en) Silanes with hydrophilic groups, their synthesis and use as surfactants in aqueous media
AU6916996A (en) Polyalkylene ethers as plasticizers and flow aids in poly(1,4-cyclohexanedimethylene terephthalate) resins
NZ336961A (en) Polymer blend comprising a polyester, a polyfunctional acid anhydride and a polyhydric alcohol
CA2203765A1 (fr) Protease cathepsine o2
EP0584876A3 (en) Low diol polyalkylene oxide biologically active proteinaceous substances
AU2755688A (en) Aqueous dispersion of particulate water soluble polymers in polyethylene glycol
AU4250897A (en) Balloon catheters having ultrasonically driven interface surfaces and methods for their use
AU4649189A (en) Alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
IT1236555B (it) Metodo per la trasmissione di informazioni nelle comunicazioni, in un sistema telefonico mobile a breve portata ed unita' radio per applicare detto metodo.
ZA865667B (en) Water-based functional fluid thickening combinations or surfactants and hydrocarbyl-substituted acid and/or anhydride/amine terminated poly(oxyalkylene)reaction products
AU8314387A (en) High molecular compound comprising unit of asialoglycoprotein acceptor-directing compound and unit of chelate-forming compound chemically bonded thereto, and its utilization
EP0602845A3 (en) Message dispatching in an event driven architecture.
EP0648242A1 (fr) POLYMERISATION DE LA LIGNINE A UN pH ALCALIN.
EP0380750A3 (fr) Polymère de glycidylazide et procédé de préparation
WO1989008673A3 (fr) Polyesters hydrophiles modifies
AU5274690A (en) Two-stage pumping apparatus with low shear first stage
AU8438998A (en) Glycidyl ether aliphatic polyalcohols as coupling agents in anionic polymerization
AU5444494A (en) 1.8''pcmcia compatible drive having two or more disks
ITRM930157A0 (it) Diaframma per modulo di innesto e suo modulo di innesto, in particolare per autoveicoli.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA